Therapeutic Asset Ratings

157 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8) latent myostatin complex], humanized monoclonal antibody; Spinal Muscular Atrophy (SMA)	Hoffmann-La Roche	P2/3	B (57)
Enicepatide Overweight	Hoffmann-La Roche	P3	B (56)
Atezolizumab Follicular Lymphoma	Hoffmann-La Roche	P2	B (56)
Gdc-0068 Neoplasms	Hoffmann-La Roche	P2	B (56)
SERUM AMYLOID P-COMPONENT, RECOMBINANT Idiopathic Pulmonary Fibrosis	Hoffmann-La Roche	P3	CCC (55)
Atezolizumab Rectal Cancer	Hoffmann-La Roche	P2	CCC (55)
Crovalimab Sickle Cell Disease	Hoffmann-La Roche	P2	CCC (55)
Gdc-0068 Prostate Cancer	Hoffmann-La Roche	P2	CCC (55)
prx002 Parkinson's Disease	Hoffmann-La Roche	P2	CCC (55)
Tiragolumab PD-L1-selected Solid Tumors	Hoffmann-La Roche	P2	CCC (55)
Trastuzumab Emtansine Bladder Cancer	Hoffmann-La Roche	P2	CCC (54)
Entrectinib Adult Solid Tumor	Hoffmann-La Roche	P2	CCC (53)
Entrectinib Head and Neck Neoplasms	Hoffmann-La Roche	P2	CCC (53)
Entrectinib Lymphoma, Large-Cell, Anaplastic	Hoffmann-La Roche	P2	CCC (53)
Entrectinib Papillary Thyroid Cancer	Hoffmann-La Roche	P2	CCC (53)
Entrectinib Primary Brain Tumors	Hoffmann-La Roche	P2	CCC (53)
Entrectinib Salivary Gland Cancers	Hoffmann-La Roche	P2	CCC (53)
immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8) latent myostatin complex], humanized monoclonal antibody; Overweight With One Weight Related Comorbidity	Hoffmann-La Roche	P2	CCC (53)
LISPRO-PH20 COMPONENT RHUPH20 Relapsing-remitting Multiple Sclerosis	Hoffmann-La Roche	P2	CCC (53)
L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-?-glutamyl-L-arginyl-L-?-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L-lysyl-L-alanyl-L-threonyl-L-?-glutamyl-L-arginyl-L-leucyl-L-alanyl-5-carboxy-L-norvalyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-seryl-L-phenylalanyl-N-methylglycyl-L-alanyl-N-methyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-?-glutamyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-4-hydroxy-, (3?8)-lactam, (4R)- Obesity	Hoffmann-La Roche	P2	CCC (53)
Ocrelizumab Co-Formulated With Rhuph20 Relapsing-remitting Multiple Sclerosis	Hoffmann-La Roche	P2	CCC (53)
Ocrevus Progressive Multiple Sclerosis	Hoffmann-La Roche	P2	CCC (53)
ro7268489 Progressive Multiple Sclerosis	Hoffmann-La Roche	P2	CCC (53)
Satralizumab Duchenne Muscular Dystrophy	Hoffmann-La Roche	P2	CCC (53)
Tiragolumab Rectal Neoplasms	Hoffmann-La Roche	P2	CCC (53)

Showing 51 to 75 of 157 assets

PreviousPage 3 of 7Next